HYDERABAD, India, Feb 24 (Reuters) - U.S. drugmaker Amgen (AMGN.O), opens new tab will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said at the inauguration of the site on Monday.
Amgen announced its plans to open a "technology and innovation" site in India last year that is focused on increasing the use of AI and data science to support development of new medicines.
"We have wanted for a long time to expand Amgen's presence in India and that time has come. Amgen is investing an initial $200 million in this centre in 2025 and plan to make additional significant investments in future years," Bradway said.
The site in Hyderabad city is expected to have a workforce of about 2,000 by year-end, with around 300 employees already working there, said Som Chattopadhyay, national executive for India at Amgen.
Hyderabad will also host the BioAsia conference this week, where executives from drugmakers including Amgen, Eli Lilly (LLY.N), opens new tab and Novartis (NOVN.S), opens new tab, as well as several Indian pharmaceutical giants will be speaking.